4-({4-[(4-tert-butoxycarbonylamino-1-methyl-1H-pyrrole-2-carbonyl)amino]-1-methyl-1H-imidazole-2-carbonyl}amino)-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester | 864672-93-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-({4-[(4-tert-butoxycarbonylamino-1-methyl-1H-pyrrole-2-carbonyl)amino]-1-methyl-1H-imidazole-2-carbonyl}amino)-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester
• 英文别名: Methyl 1-methyl-4-[[1-methyl-4-[[1-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]pyrrole-2-carbonyl]amino]imidazole-2-carbonyl]amino]pyrrole-2-carboxylate
• CAS: 864672-93-5
• 化学式: C₂₃H₂₉N₇O₆
• 分子量: 499.527
• InChiKey: LDTHAKPALPJCGW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  151
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-({4-[(4-tert-butoxycarbonylamino-1-methyl-1H-pyrrole-2-carbonyl)amino]-1-methyl-1H-imidazole-2-carbonyl}amino)-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester 在 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 0.5h， 生成 C₁₈H₂₁N₇O₄
  参考文献：
  名称：

  An Extended Pyrrolobenzodiazepine–Polyamide Conjugate with Selectivity for a DNA Sequence Containing the ICB2 Transcription Factor Binding Site

  摘要：

  The binding of nuclear factor Y (NF-Y) to inverted CCAAT boxes (ICBs) within the promoter region of DNA topoisomerase II alpha results in control of cell differentiation and cell cycle progression. Thus, NF-Y inhibitory small molecules could be employed to inhibit the replication of cancer cells. A library of pyrrolobenzodiazepine (PBD) C8-conjugates consisting of one PBD unit attached to tri-heterocyclic polyamide fragments was designed and synthesized. The DNA-binding affinity and sequence selectivity of each compound were evaluated in DNA thermal denaturation and DNase I footprinting assays, and the ability to inhibit binding of NF-Y to ICB1 and ICB2 was studied using an electrophoretic mobility shift assay (EMSA). 3a was found to be a potent inhibitor of NF-Y binding, exhibiting a 10-fold selectivity for an ICB2 site compared to an ICB1-containing sequence, and showing low nanomolar cytotoxicity toward human tumor cell lines. Molecular modeling and computational studies have provided details of the covalent attachment process that leads to formation of the PBD-DNA adduct, and have allowed the preference of 3a for ICB2 to be rationalized.

  DOI：

  10.1021/jm4001852
• 作为产物：
  描述：

  ethyl 4-[4-[(tert-butoxycarbonyl)amino]-1-methylpyrrole-2-amido]-1-methylimidazole-2-carboxylate 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 水 、 N,N-二异丙基乙胺 、 lithium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 4-({4-[(4-tert-butoxycarbonylamino-1-methyl-1H-pyrrole-2-carbonyl)amino]-1-methyl-1H-imidazole-2-carbonyl}amino)-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester
  参考文献：
  名称：

  WO2022/150555

  摘要：

  公开号：

文献信息

• [EN] C8, C8' LINKED 5-OXO-1,2,3,11A-TETRAHYDRO-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPINE DIMERS WITH 1H-PYRROLE-DICARBOXYLIC ACID AMIDE LINKERS AND OLIGOMERIC ANALOGS THEROF AS WELL AS RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DIMERES DE C8,C8' 5-OXO-1,2,3, 11A-TETRAHYDRO-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPINE LIES PAR DES LIEURS D'AMIDE D'ACIDE 1-H-PYRROLE-DICARBOXYLIQUE ET LEURS ANALOGUES OLIGOMERES AINSI QUE DES COMPOSES CONNEXES DESTINES AU TRAITEMENT DE MALADIES PROLIFERATIVES
  申请人：SPIROGEN LTD

  公开号：WO2005085250A1

  公开（公告）日：2005-09-15

  Compounds of formula (I): PBD-A-Y-X- (Het)na-L- (Het)nb-L- (Het)nc-T- (Het')nd-L- (Het')ne-L- (Het')nf-X' -Y' -A' -PBD' and salts, solvates and chemically protected forms thereof, are disclosed wherein the PBD units have the formulae (PBD) (PBD') with the bonds at the 8 position on each molecule bond to the A and A' groups respectively ; A is selected from O, S, NH or a single bond , and each Het and Het' is respectively an amino-heteroarylene-carbonyl group ; X and X' are both either NH or C (=O) -Q-C (=O) - wherein Q is a divalent group such that HY = R ; in a second aspectm the invention comprises compounds of the general formula (II) : PBD-A-Y-X-(Het)ng-[L-(Het)nh] nj-X' -Y' -A' -PBD'. Wherein : PBD and PBD' are as defined above, X and X' are either NH and C(=O) respectively or C(O) and NH respectively ; the other substituents are defined in the claims. Further aspects of the present invention relate to their use in the manufacture of a medicament for the treatment of a proliferative disease.

  公式（I）的化合物：PBD-A-Y-X-（Het）na-L-（Het）nb-L-（Het）nc-T-（Het'）nd-L-（Het'）ne-L-（Het'）nf-X'-Y'-A'-PBD'及其盐、溶剂合物和化学保护形式，其中PBD单位具有化学式（PBD）（PBD'），每个分子的8位置的键分别与A和A'基团结合；A从O、S、NH或单键中选择，每个Het和Het'分别为氨基-杂芳基-羰基基团；X和X'都是NH或C（=O）-Q-C（=O）-，其中Q是二价基团，使得HY = R；在第二方面，本发明涉及一般化学式（II）的化合物：PBD-A-Y-X-(Het)ng-[L-(Het)nh] nj-X'-Y'-A'-PBD'。其中：PBD和PBD'如上所定义，X和X'分别为NH和C（=O）或C（O）和NH；其他取代基在权利要求中定义。本发明的其他方面涉及它们在制造用于治疗增殖性疾病的药物中的用途。
• Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease
  申请人：Howard Philip Wilson

  公开号：US20080214525A1

  公开（公告）日：2008-09-04

  A compound of formula (I); or a salt or solvate thereof, wherein: the dotted line indicates the optional presence of a double bond between C2 and C3; R 2 is selected from —H, —OH, =0, ═CH 2 , —CN, —R, OR, halo, ═CH—R, O—SO 2 —R, CO 2 R and COR; R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, nitro, Me 3 Sn and halo, where R and R′ are independently selected from optionally substituted C 1-7 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups; R 10 and R 11 either together form a double bond, or are selected from H and YR Y , where Y is selected from O, S and NH and R is H or C 1-7 alkyl or H and SO x M, where x is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; each X is independently a heteroarylene group; n is from 1 to 6; and R E is C 1-4 alkyl. The compound is useful for the treatment of proliferative diseases.

  化合物的公式（I）；或其盐或溶剂化物，其中：虚线表示C2和C3之间的双键是可选的；R2选择自-H，-OH，=0，═CH2，-CN，-R，OR，卤基，═CH-R，O-SO2-R，CO2R和COR；R7选择自H，R，OH，OR，SH，SR，NH2，NHR，NRR'，硝基，Me3Sn和卤基，其中R和R'独立选择自可选取代的C1-7烷基，C3-20杂环基和C5-20芳基基团；R10和R11要么一起形成双键，要么选择自H和YRY，其中Y选择自O，S和NH，R为H或C1-7烷基或H和SOxM，其中x为2或3，M为一价的药用可接受阳离子；每个X独立地是杂芳基基团；n为1至6；以及RE为C1-4烷基。该化合物可用于治疗增殖性疾病。
• C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4] benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs therof as well as related compounds for the treatment of proliferative diseases
  申请人：Howard Wilson Philip

  公开号：US20070191349A1

  公开（公告）日：2007-08-16

  Compounds of formula (I): PBD-A-Y—X—(Het) na -L-(Het) nb -L-(Het) nc -T-(Het′) nd -L-(Het′) ne -L-(Het′) nf —X′—Y′- A′-PBD′ and salts, solvates and chemically protected forms thereof, are disclosed wherein the PBD units have the formulae (PBD) (PBD′) with the bonds at the 8 position on each molecule bond to the A and A′ groups respectively; A is selected from O, S, NH or a single bond, and each Het and Het′ is respectively an amino-heteroarylene-carbonyl group; X and X′ are both either NH or C (═O)-Q—C(═O)— wherein Q is a divalent group such that HY═R; in a second aspectm the invention comprises compounds of the general formula (II): PBD-A-Y—X—(Het) ng -[L-(Het) nh ] nj -X′—Y′-A′-PBD′. Wherein: PBD and PBD′ are as defined above, X and X′ are either NH and C(═O) respectively or C(O) and NH respectively; the other substitutents are defined in the claims. Further aspects of the present invention relate to their use in the manufacture of a medicament for the treatment of a proliferative disease.

  公式（I）的化合物：PBD-A-Y—X—（Het）na-L-（Het）nb-L-（Het）nc-T-（Het′）nd-L-（Het′）ne-L-（Het′）nf—X′—Y′-A′-PBD′及其盐，溶剂化物和化学保护形式，其中PBD单元具有式（PBD）（PBD′），每个分子上8位置的键分别与A和A'基团结合；A选择自O，S，NH或单键，每个Het和Het′分别是氨基杂芳基羰基基团；X和X′均为NH或C（═O）-Q-C（═O）-，其中Q是二价基团，使得HY═R；在第二方面，本发明涉及一般式（II）的化合物：PBD-A-Y—X—（Het）ng-[L-（Het）nh]nj-X′—Y′-A′-PBD′。其中：PBD和PBD′如上所定义，X和X′分别为NH和C（═O）或C（O）和NH；其他取代基在权利要求中定义。本发明的进一步方面涉及它们在制造用于治疗增殖性疾病的药物中的使用。
• ALKYL 4- [4- (5-OXO-2, 3, 5, 11A-TETRAHYD0-5H-PYRR0L0 [2, 1-C][1, 4]BENZODIAZEPINE-8-YLOXY) -BUTYRYLAMINO]-1H-PYRROLE-2-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF A PROLIFERATIVE DISEASE
  申请人：Spirogen Limited

  公开号：EP1931671B1

  公开（公告）日：2009-04-08
• US8637664B2
  申请人：——

  公开号：US8637664B2

  公开（公告）日：2014-01-28